Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 01, 2015 3:31 PM ET

Biotechnology

Company Overview of Audentes Therapeutics, Inc.

Company Overview

Audentes Therapeutics, Inc., a biotechnology company, engages in the development and commercialization of new treatments for people with serious rare muscle diseases through the application of adeno-associated virus gene therapy technology. Its treatments include AT001 for the treatment of X-linked myotubular myopathy; and AT002 for the treatment of pompe disease. Audentes Therapeutics, Inc. was founded in 2012 and is based in San Francisco, California.

San Francisco, CA 

United States

Founded in 2012

Key Executives for Audentes Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 43
Chief Medical Officer and Senior Vice President
Senior Vice President of Preclinical Development and Translational Medicine
Senior Vice President of Regulatory Affairs and Quality Assurance
Vice President of Corporate Development
Compensation as of Fiscal Year 2015.

Audentes Therapeutics, Inc. Key Developments

Audentes Therapeutics Receives Orphan Drug Designation for AT001 for the Treatment of X-Linked Myotubular Myopathy in the US and Europe

Audentes Therapeutics, Inc. announced that AT001, an investigational product in development for the treatment of X-Linked Myotubular Myopathy (XLMTM), has been granted orphan designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). XLMTM is a rare, severe, inherited disorder that affects skeletal muscles from birth. The disease is caused by mutations in the MTM1 gene, which encodes an enzyme called myotubularin. Myotubularin plays an important role in the development, maintenance and function of muscle cells. AT001 is a novel product based on adeno-associated virus (AAV) gene therapy technology that is designed to restore the ability of skeletal muscle to produce myotubularin. Administration of AT001 has resulted in improved muscle strength and survival in a murine model of XLMTM as well as improved muscle strength, respiratory symptoms and survival in a canine model of the disease. The FDA and EMA Orphan Drug programs provide orphan designation to drugs and biologics that are intended for the treatment of rare diseases (those affecting fewer than 200,000 people in the United States or 5 in 10,000 in the EU). The designation provides sponsors with development and commercial incentives including, seven years of market exclusivity in the US, 10 years of market exclusivity in the EU, consultation by FDA and EMA on clinical study design, and certain fee exemptions and reductions.

Audentes Therapeutics, Inc. Presents at Piper Jaffray GenomeRx Symposium, May-20-2015

Audentes Therapeutics, Inc. Presents at Piper Jaffray GenomeRx Symposium, May-20-2015 . Venue: The New York Palace Hotel, New York, New York, United States. Speakers: John T. Gray, Vice President of Research and Development, Matthew R. Patterson, Chief Executive Officer, President and Director.

Audentes Therapeutics Appoints Stephen Squinto to its Board of Directors

Audentes Therapeutics, Inc. announced the appointment of Stephen Squinto, Ph.D., to the company's Board of Directors. Dr. Squinto, a co-founder of Alexion Pharmaceuticals, Inc., will serve as an independent director to Audentes. Stephen Squinto, Ph.D., has over 25 years of experience in the biotechnology industry, as both a scientist and senior executive. He is currently a Venture Partner with OrbiMed. Dr. Squinto was a co-founder of Alexion Pharmaceuticals Inc. and recently served as its Executive Vice President and Chief Global Operations Officer.

Similar Private Companies By Industry

Company Name Region
Restorative Biosciences Inc. United States
Mymetics Corporation United States
PhosImmune Inc. United States
Molecular Transfer, Inc. United States
Anchor Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
November 21, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Audentes Therapeutics, Inc., please visit www.audentestx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.